BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND BCR, FLJ16453, 613, ENSG00000186716, BCR1, D22S662, D22S11, CML, P11274, PHL, ALL AND Treatment
76 results:

  • 1. Association between hospital volume and outcomes in invasive ovarian cancer in Belgium: A population-based study.
    Savoye I; Silversmit G; Bourgeois J; De Gendt C; Leroy R; Peacock HM; Stordeur S; de Sutter P; Goffin F; Luyckx M; Orye G; Van Dam P; Van Gorp T; Verleye L
    Eur J Cancer; 2023 Dec; 195():113402. PubMed ID: 37922631
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. treatment of Recurrent Low-grade Serous ovarian cancer With MEK Inhibitors: A Systematic Review.
    Kulkarni A; Cooke C; Fazelzad R; Fung-Kee-Fung M; May T; Zigras T
    Am J Clin Oncol; 2024 Jan; 47(1):11-16. PubMed ID: 37823720
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Bevacizumab treatment for Low-Grade Serous ovarian cancer: A Systematic Review.
    Lazurko C; Linder R; Pulman K; Lennox G; Feigenberg T; Fazelzad R; May T; Zigras T
    Curr Oncol; 2023 Sep; 30(9):8159-8171. PubMed ID: 37754507
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Cost-effectiveness of Myomectomy versus Hysterectomy in Women with Uterine Fibroids.
    Thao V; Moriarty JP; Stewart EA; Borah BJ
    J Minim Invasive Gynecol; 2023 Oct; 30(10):813-819. PubMed ID: 37286130
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. A retrospective analysis of secondary cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in patients with recurrent ovarian cancer.
    Yang D; Zhang Y; Gong P; Liu F; Gan Y; Bai W
    J Obstet Gynaecol Res; 2023 Jul; 49(7):1795-1804. PubMed ID: 37231941
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Lymphocyte-activation gene 3 protein expression in tumor-infiltrating lymphocytes is associated with a poor prognosis of ovarian clear cell carcinoma.
    Zaitsu S; Yano M; Adachi S; Miwa M; Katoh T; Kawano Y; Yasuda M
    J Ovarian Res; 2023 May; 16(1):93. PubMed ID: 37179337
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials.
    Rozkiewicz D; Hermanowicz JM; Kwiatkowska I; Krupa A; Pawlak D
    Molecules; 2023 Mar; 28(5):. PubMed ID: 36903645
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Minimal residual disease detection by mutation-specific droplet digital PCR for leukemia/lymphoma.
    Shirai R; Osumi T; Keino D; Nakabayashi K; Uchiyama T; Sekiguchi M; Hiwatari M; Yoshida M; Yoshida K; Yamada Y; Tomizawa D; Takae S; Kiyokawa N; Matsumoto K; Yoshioka T; Hata K; Hori T; Suzuki N; Kato M
    Int J Hematol; 2023 Jun; 117(6):910-918. PubMed ID: 36867356
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Clinical characteristics and survival analysis of Chinese ovarian cancer patients with RAD51D germline mutations.
    Yao H; Li N; Yuan H
    BMC Cancer; 2022 Dec; 22(1):1337. PubMed ID: 36544182
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Single-cell sequencing reveals effects of chemotherapy on the immune landscape and TCR/bcr clonal expansion in a relapsed ovarian cancer patient.
    Ren Y; Li R; Feng H; Xie J; Gao L; Chu S; Li Y; Meng F; Ning Y
    Front Immunol; 2022; 13():985187. PubMed ID: 36248860
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Survival benefits of retroperitoneal lymphadenectomy for optimally-resected advanced ovarian high-grade serous carcinoma: a multi-institutional retrospective study.
    Ikeda Y; Yoshihara M; Tamauchi S; Yokoi A; Yoshikawa N; Kajiyama H
    J Gynecol Oncol; 2022 Jul; 33(4):e40. PubMed ID: 35320889
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Gemtuzumab-ozogamicin and blinatumomab as treatment for refractory mixed-phenotype blast crisis in chronic myeloid leukaemia.
    Ovilla-Martinez R; Weber Sánchez LA; Cota-Rangel X; Baez-Islas PE
    BMJ Case Rep; 2021 Nov; 14(11):. PubMed ID: 34764108
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Secondary cytoreductive surgery for recurrent low-grade serous ovarian carcinoma: A systematic review and meta-analysis.
    Goldberg RM; Kim SR; Fazelzad R; Li X; Brown TJ; May T
    Gynecol Oncol; 2022 Jan; 164(1):212-220. PubMed ID: 34756470
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Fertility preservation in breast cancer with oral progestin: is it an option? A pilot study.
    Oliveira R; Maya BG; Nogueira MBS; Conceição GS; Bianco B; Barbosa CP
    Einstein (Sao Paulo); 2021; 19():eAO5859. PubMed ID: 34431852
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Disease-inducing potential of two leukemic cell lines in a xenografting model.
    Manavella DD; Herraiz S; Soares M; Buigues A; Pellicer A; Donnez J; Díaz-García C; Dolmans MM
    J Assist Reprod Genet; 2021 Jun; 38(6):1589-1600. PubMed ID: 33786735
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Phase II consolidation trial with anti-Lewis-Y monoclonal antibody (hu3S193) in platinum-sensitive ovarian cancer after a second remission.
    Smaletz O; Ismael G; Del Pilar Estevez-Diz M; Nascimento ILO; de Morais ALG; Cunha-Junior GF; Azevedo SJ; Alves VA; Moro AM; Yeda FP; Dos Santos ML; Majumder I; Hoffman EW
    Int J Gynecol Cancer; 2021 Apr; 31(4):562-568. PubMed ID: 33664128
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Female reproductive function after treatment of childhood acute lymphoblastic leukemia.
    Roshandel R; van Dijk M; Overbeek A; Kaspers G; Lambalk C; Beerendonk C; Bresters D; van der Heiden-van der Loo M; van den Heuvel-Eibrink M; Kremer L; Loonen J; van der Pal H; Ronckers C; Tissing W; Versluys B; van Leeuwen F; van den Berg M; van Dulmen-den Broeder E;
    Pediatr Blood Cancer; 2021 Apr; 68(4):e28894. PubMed ID: 33459500
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Characterization of therapy-related acute leukemia in hereditary breast-ovarian carcinoma patients: role of BRCA1 mutation and topoisomerase II-directed therapy.
    Bagal B; Kumar R; Gaur T; Talreja V; Bonda A; Patkar N; Shetty D; Kowtal P; Subramanian PG; Gupta S; Sarin R; Hasan SK
    Med Oncol; 2020 Apr; 37(5):48. PubMed ID: 32277283
    [TBL] [Abstract] [Full Text] [Related]  

  • 19.
    Vitale SR; Groenendijk FH; van Marion R; Beaufort CM; Helmijr JC; Dubbink HJ; Dinjens WNM; Ewing-Graham PC; Smolders R; van Doorn HC; Boere IA; Berns EMJJ; Helleman J; Jansen MPHM
    Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32156073
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Comparison of CA 125 alone and risk of ovarian malignancy algorithm (ROMA) in patients with adnexal mass: A multicenter study.
    Choi HJ; Lee YY; Sohn I; Kim YM; Kim JW; Kang S; Kim BG
    Curr Probl Cancer; 2020 Apr; 44(2):100508. PubMed ID: 31708114
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 4.